Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of QTP104 COVID-19 Vaccine in Healthy Adults
NCT05876364Phase 1Unknown
- Sponsor
- Quratis
- Start
- Nov 2021
- Primary completion
- Jun 2022
- Modality
- Nanoparticles, mRNA Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HDT-301 in coronavirus disease 2019 (COVID-19) (3 cohorts), sponsored by Quratis. Primary endpoints: Adverse events (Immediate AEs), Adverse event (solicited local / systemic AEs) and 3 more. Status: unknown.
02
Drugs
HDT-301
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05876364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05876364.